Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Daiichi Sankyo

Status and phase: Completed; Phase 3

Conditions: Hypertension

Treatments: Drug: CS-3150

Study type: Interventional

Funder types: Industry

Identifiers

NCT02807974

CS3150-A-J306

Details and patient eligibility

About

To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with type 2 diabetes and albuminuria.

Enrollment: 51 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female subjects aged 20 to 80 years at informed consent
• Subjects with type 2 diabetes and albuminuria (urine albumin-to-creatinine ratio ≥ 30, < 1000 mg/g/Cr)
• Subjects with hypertension (Sitting SBP ≥ 140 mmHg, <180 mmHg and Sitting DBP ≥ 80 mmHg, <110 mmHg
• Treatment with an ARB or ACE inhibitor
• eGFR ≥ 30 mL/min/1.73m^2

Exclusion criteria

• Secondary hypertension or malignant hypertension
• Type 1 diabetes
• Secondary glucose intolerance
• Diagnosed with non-diabetic nephropathy
• Serum potassium level < 3.5 or ≥ 4.8 mEq/L

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

51 participants in 1 patient group

CS-3150

Experimental group

Description:

CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks

Treatment:

Drug: CS-3150